(Q40631933)

English

An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group

scientific article published on September 1999

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Höffken G

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Pasold R

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Pflüger KH

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Finke J

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Fauser AA

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Szelenyi H

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Wagner J

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

1 September 1999

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

367-376

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Single or multiple daily doses of aminoglycosides: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Bactericidal Activity of Cephalosporins in an In Vitro Model Simulating Serum Levels

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.3.367

21 January 2018

Identifiers

10.1093/JAC/44.3.367

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

release_ti2vj7yzlbhsbn5ujn4ih45iqi

1 reference

https://api.fatcat.wiki/v0/release/ti2vj7yzlbhsbn5ujn4ih45iqi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40631933&oldid=1903809750"